Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3622 - Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Multiple Meyloma

Presenters

Sergey Semochkin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

S. Semochkin1, E. Zhelnova2, E. Misyurina2, T. Tolstykh2, N. Arkhipova2, E. Baryakh2, E. Grishina2, E. Karimova2, O. Kochneva2, E. Mavrina2, Y. Polyakov2, E. Yaskova2

Author affiliations

  • 1 Oncology, Hematology And Radiotherapy, Pirogov Russian National Research Medical University, 117997 - Moscow/RU
  • 2 Hemalology, Moscow City Hospital #52, 123182 - Moscow/RU
More

Resources

Abstract 3622

Background

About 2-4% of patients with newly diagnosed multiple myeloma (MM) present with severe dialysis required renal failure (RF), which is associated with significant morbidity and early death. The aim of this article was to analyze own experience in treating this category.

Methods

During 10.2014-12.2017 the sixty-two patients with severe RF with a glomerular filtration rate (eGFR) <30 ml/min/1.73m2 were enrolled in this retrospective study. All patients received bortezomib-based regimens: 41 (66.1%) VDC; 2 (3.2%) PAD; 12 (19.4%) VD and 7 (11.3%) VMP. Seven (11.3%) patients underwent high-dose therapy with ASCT. IMWG (2010) renal response criteria were used. Myeloma response was evaluated using the standard IMWG (2006) criteria.

Results

At the time of presentation 48 (77%) patients required dialysis. The mean eGFR was 6.0 (95% CI 4.4-7.6) for patients requiring dialysis (Group A) and 22.2 (16.4-29.2) ml/min/1.73 m2 for those (Group B) are a dialysis independent (P < 0.001). Mean level of involved free light chain (iFLC) was 7400 (3440-10840) mg/l vs 2900 (780-5020) mg/l respectively (P < 0.001). The median time from RF to start of MM chemotherapy comprise 39 and 21 days for two groups respectively. Six (9.7%) patients died within the first 60 days of therapy (induction mortality). At least minimal renal response ( > =MRrenal) documented in 23.5% and 57.1% patients respectively. If the duration RF before initiation of MM treatment was >1 month no one patient required dialysis restored a renal function. Among all patients, overall myeloma response ( > =PR) documented in 81% cases, including 39.6% very good partial response (VGPR) and 14.6% complete response (CR/sCR). Two-years overall survival (OS) was 67.8 ± 6.4% without any different between groups.

Conclusions

In conclusion, our data indicate that bortezomib-based triplets are associated with a significant probability of renal response. In at least a 23.5% of patients with MM presenting with dialysis-requiring severe RF may improve their renal function and discontinue dialysis. Unfortunately, our results are inferior to the literature data according to which up to 50% of patients become independent of dialysis.

Clinical trial identification

Legal entity responsible for the study

Evgeniya Zhelnova.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.